Table 1.
Baseline patient characteristics
| Characteristic | All, n = 12 |
|---|---|
| Age, years | |
| Median | 68 |
| Range | 51–86 |
| Sex, n (%) | |
| Female | 4 (33.3) |
| Male | 8 (66.7) |
| Race, n (%) | |
| White | 10 (83.3) |
| Black or African American | 2 (16.7) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 1 (8.3) |
| Non-Hispanic | 11 (91.7) |
| Primary site, n (%) | |
| Bladder | 7 (58.3) |
| Upper tract | 4 (33.3) |
| Urethra | 1 (8.3) |
| Number of prior systemic therapy regimensa, n (%) | |
| 1 | 7 (58.3) |
| 2 | 3 (25.0) |
| 3 | 2 (16.7) |
| Setting of prior platinum-based chemotherapy, n (%) | |
| Perioperative only | 8 (66.7) |
| Metastatic only | 2 (16.7) |
| Both | 2 (16.7) |
| ECOG performance status, n (%) | |
| 0 | 5 (41.7) |
| 1 | 6 (50.0) |
| 2 | 1 (8.3) |
| Hemoglobin, n (%) | |
| <10 g/dL | 2 (16.7) |
| ≥10 g/dL | 10 (83.3) |
| Liver metastases, n (%) | |
| Yes | 0 |
| No | 12 (100) |
| Time from prior therapy, n (%) | |
| <3 months | 4 (33.3) |
| 3–6 months | 5 (41.7) |
| 6–9 months | 1 (8.3) |
| ≥12 months | 2 (16.7) |
ECOG PS Eastern Cooperative Oncology Group performance status
aIncludes immunotherapy